koto_feja/iStock via Getty Images
Genmab (GMAB) on Friday announced that its bispecific antibody epcoritamab, marketed as Epkinly in partnership with AbbVie (ABBV), extended patient survival without tumor progression in a late-stage trial for diffuse large B-cell lymphoma (DLBCL).
However, Genmab (GMAB) lost ~7% after the